Personalized Medicine May Necessitate Increased Focus On Drug Quality
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Office of Biotechnology Products Director says promise of personalized medicine may place greater burden on pharma to ensure drugs work as intended in target populations.
You may also be interested in...
‘Precision Medicine’ Gets R&D Funding Push In President’s Speech
President Obama highlights potential for personalized medicine in his State of the Union address and will seek a “major increase” in research and development funding.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.